Engineered immune cells take aim at deadly brain cancers
NCT ID NCT07180927
Summary
This study is testing a new type of personalized immunotherapy called CAR-T for patients with aggressive, hard-to-treat brain tumors that have come back after standard treatments. Doctors take a patient's own immune cells, modify them in a lab to recognize a specific protein (DLL3) found on the tumor cells, and then infuse them back into the patient to attack the cancer. The main goals are to see if this approach is safe and if it shows signs of shrinking tumors in patients aged 2 to 70.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA OF CEREBELLUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immuno Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.